Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place ...

Recent performance and business mix Merck KGaA (XTRA:MRK) has drawn investor attention after a mixed share performance, with an 8.3% gain over the past month set against a 9.1% decline over the past 3 ...

In the trailing-twelve-months (TTM) as of 3/24/26, 64% of the companies in the S&P 500 reported GAAP Earnings that are lower ...

The Cancer Calculus, coordinated by the International Consortium of Investigative Journalists with Deutsche Welle and 46 ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first announced in July. It brings the chronic ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully reducing bad cholesterol in a late-stage head-to-head trial with other therapies ...

Merck Foundation marks ‘World Art Day’ through their Film, Song, Media and Fashion Awards 2026 in partnership with Africa’s First Ladies to raise awareness about social & health issues ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on ...